Li Mu-Xing, Zhao Hong, Bi Xin-Yu, Li Zhi-Yu, Huang Zhen, Han Yue, Zhou Jian-Guo, Zhao Jian-Jun, Zhang Ye-Fan, Cai Jian-Qiang
Department of Abdominal Surgical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Interventional Therapies, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Hepatol Res. 2017 Jul;47(8):731-741. doi: 10.1111/hepr.12796. Epub 2016 Nov 3.
The prognostic value of the newly raised objective liver function assessment tool, the albumin-bilirubin (ALBI) grade, in patients with hepatocellular carcinoma has not been fully validated. We aimed to compare the performance of ALBI grade with the specific Child-Pugh (C-P) score in predicting prognosis in this study.
The clinical data of 491 C-P class A patients who underwent liver resection as initial therapy from January 2000 to December 2007 in Cancer Hospital, Chinese Academy of Medical Sciences (Beijing, China) were retrospectively analyzed. The prognostic performances of ALBI and C-P score in predicting the short- and long-term clinical outcomes were compared.
The ALBI score gained a significantly larger area under the receiver operating characteristic curve for predicting the occurrence of severe postoperative complications than that of C-P score. With a median follow-up of 57 months, the 1-year, 3-year, and 5-year overall survival rates of the patients were 92.1%, 65.8%, and 45.2%, respectively. Tumor number, tumor size, and ALBI grade were proved to be the independent prognostic factors for overall survival in the multivariate analysis. Prognostic performance was shown to be better for ALBI grade when it was compared to C-P score in terms of both the Akaike information criterion value and χ value of likelihood ratio test.
The ALBI grade, which was featured by simplicity and objectivity, gained a superior prognostic value than that of C-P grade in patients with hepatocellular carcinoma who underwent liver resection. Future well-designed studies with larger sample sizes are warranted.
新提出的客观肝功能评估工具——白蛋白-胆红素(ALBI)分级在肝细胞癌患者中的预后价值尚未得到充分验证。在本研究中,我们旨在比较ALBI分级与特定的Child-Pugh(C-P)评分在预测预后方面的表现。
回顾性分析了2000年1月至2007年12月在中国医学科学院肿瘤医院(北京,中国)接受肝切除作为初始治疗的491例C-P A级患者的临床资料。比较了ALBI和C-P评分在预测短期和长期临床结局方面的预后表现。
在预测严重术后并发症的发生方面,ALBI评分在受试者工作特征曲线下的面积显著大于C-P评分。中位随访57个月,患者的1年、3年和5年总生存率分别为92.1%、65.8%和45.2%。在多变量分析中,肿瘤数量、肿瘤大小和ALBI分级被证明是总生存的独立预后因素。在赤池信息准则值和似然比检验的χ值方面,与C-P评分相比,ALBI分级的预后表现更好。
以简单性和客观性为特征的ALBI分级在接受肝切除的肝细胞癌患者中比C-P分级具有更高的预后价值。未来有必要进行设计良好的大样本研究。